

THE LANCET

Supplementary appendix

This appendix formed part of the original submission and has been peer reviewed.
We post it as supplied by the authors.

Supplement to: Ziegler A-G, Cengiz E, Kay TWH. The future of type 1 diabetes therapy. *Lancet* 2025; published online Sept 19. [https://doi.org/10.1016/S0140-6736\(25\)01438-2](https://doi.org/10.1016/S0140-6736(25)01438-2).

Therapeutics Review - The Future of Type 1 Diabetes Therapy

Anette-Gabriele Ziegler, Eda Cengiz, Thomas W. H. Kay

Search terms

Pubmed:

“type 1 diabetes AND”,
“disease-modifying therapy”,
“immunotherapy”,
“adjunct therapies”,
“anti-CD3”,
“JAK-inhibitor”,
“baricitinib”,
“ATG”, “rituximab”,
“anti-TNF”,
“IL-2”,
“DCCT”,
“C-peptide preservation”,
“verapamil”,
“Diamyd”,
“IL-23”,
“antigen-based therapy”,
“CTLA-4”,
“vaccination”,
“islet transplantation”,
“stem cell therapy”,
“embryonic stem cells”,
“Vertex-880 cells”,
“pluripotent stem cells”,
“insulin”,
“AID”,
“diabetes technology”,
“adjunctive treatment”,
“insulin”,
“smart insulin”, and
“glucose responsive insulin”

ClinicalTrials.gov

“type 1 diabetes intervention studies prevention ongoing”,
“type 1 diabetes, prevention, study type (interventional)”,
“type 1 diabetes, early stage, study type (interventional)”,
“type 1 diabetes, prediabetes, study type (interventional)”,
“type 1 diabetes, newly diagnosed, study type (interventional)”,
“type 1 diabetes, immunotherapy, study type (interventional)”,
“type 1 diabetes, anti-CD3, study type (interventional)”,
“type 1 diabetes, Rituximab, study type (interventional)”,
“type 1 diabetes, immunoplasmid therapy, study type (interventional)”,
“type 1 diabetes, nanoparticle”,
“type 1 diabetes, FABULINUS”

EudraCT:

“juvenile type 1 diabetes” – selected trial status “ongoing”